Antiepileptic potential and behavioral profile of L-pGlu-(2-propyl)-L-His-L-ProNH2, a newer thyrotropin-releasing hormone analog.
Thyrotropin-releasing hormone (TRH) and its analogs have a number of neurobiological functions and therapeutic uses in disorders of the central nervous system. In this study, the newly synthesized TRH analogs were evaluated for central nervous system activity in pentobarbital-induced sleeping in mice. The most potent TRH analog (L-pGlu-(2-propyl)-L-His-L-ProNH(2) coded as NP-647) was evaluated for its antiepileptic potential in various seizure models in mice in comparison with TRH. Intravenous pretreatment with NP-647 (10 and 20 micromol/kg body wt) significantly delayed the onset and reduced the frequency of convulsions in the pentylenetetrazole model, but not in the maximum electroshock seizure model. Also, it was found to be protective against picrotoxin- and kainic acid-induced seizures. However, NP-647 did not significantly affect theophylline-induced seizures. Further study of the effect of NP-647 on locomotor activity and a functional observational battery revealed that it did not significantly exhibit any undesirable effects as compared with vehicle and TRH. NP-647 did not significantly affect cerebral blood flow, whereas the native peptide TRH markedly increased cerebral blood flow. Furthermore, NP-647 exerted antiepileptic activity without significantly altering plasma thyroid-stimulating hormone levels and mean arterial blood pressure. This suggests that NP-647 is more selective for central nervous system activity and devoid of hormonal and cerebrovascular system effects. In contrast, TRH exhibited cardiac and endocrine effects as marked by significant elevation in mean arterial blood pressure and plasma thyroid-stimulating hormone levels. This study demonstrates that NP-647 has potential antiepileptic activity devoid of undesirable effects and, thus, can be exploited for the prevention and treatment of epilepsy.
Rajput
Satyendra Kumar
SK
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India.
Krishnamoorthy
Srinivasan
S
Pawar
Chandrasekhar
C
Kaur
Navneet
N
Monga
Vikramdeep
V
Meena
Chhuttan Lal
CL
Jain
Rahul
R
Sharma
Shyam S
SS
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use* / Q000633:toxicity; D001522:Behavior, Animal / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003292:Convulsants / Q000037:antagonists & inhibitors; D004597:Electroshock; D006993:Hypnotics and Sedatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007608:Kainic Acid / Q000037:antagonists & inhibitors; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D010852:Picrotoxin / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control; D012890:Sleep / Q000187:drug effects; D013806:Theophylline / Q000037:antagonists & inhibitors; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity
D000927:Anticonvulsants; D000697:Central Nervous System Stimulants; D003292:Convulsants; D006993:Hypnotics and Sedatives; D007608:Kainic Acid; D010433:Pentylenetetrazole; D010852:Picrotoxin; D013806:Theophylline; D013972:Thyrotropin; D013973:Thyrotropin-Releasing Hormone; C539979:pyroglutamyl-(2-propyl)histidyl-prolinamide